Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
In obese hypertensive patients, first-line treatment with eplerenone was not associated with excess renal function decline or clinically significant hyperkalemia compared with irbesartan, and these findings support the renal safety of MRA-based first-line therapy in this population.
Abstract
Mineralocorticoid receptor antagonists (MRAs) are effective antihypertensive agents; however, their use as first-line therapy remains limited due to concerns regarding hyperkalemia and renal impairment.
To compare renal function changes and hyperkalemia incidence between eplerenone- and irbesartan-based first-line treatment strategies in obese patients with essential hypertension.
HEBRO (antiHypertensive treatment with Eplerenone vs. iBesartan in hypeRtensive Obese patients) is a prospective, randomized, open-label, multicenter trial enrolling 198 hypertensive patients aged 30–75 years with obesity (BMI ≥30 kg/m²) and hypertension confirmed by both office and ambulatory blood pressure (ABPM) measurements. Patients underwent stratified randomization (according to age, sex, baseline office BP, and eGFR) to eplerenone 25 mg twice daily (n=99) or irbesartan 150 mg once daily (n=99). At 2 and 4 months, stepwise up-titration with amlodipine 5 mg and indapamide 1.5 mg, respectively, was performed if mean ABPM remained >130/80 mmHg. Renal function (eGFR, serum creatinine) and potassium were assessed at baseline and 6 months. Between-group differences in change from baseline were analyzed using appropriate independent-samples tests. Hyperkalemia was defined as serum potassium ≥5.5 mmol/L.
Baseline characteristics were balanced between groups: 50.5% men, age 55.5 ± 10.1 years, BMI 34.2 ± 3.5 kg/m², mean eGFR 85.7 ± 16.1 mL/min/1.73m², and diabetes prevalence 13.6%. A total of 162 patients were included in this safety analysis. Mean change in serum potassium was 0.02 ± 0.45 mmol/L in the eplerenone arm and 0.01 ± 0.45 mmol/L in the irbesartan arm (p=0.86). Hyperkalemia (≥5.5 mmol/L) was rare and occurred in 1.2% and 1.3% of patients, respectively (p=1.00), with no treatment discontinuations. Median change in serum creatinine was 0.00 mg/dL in both groups (p=0.70). Similarly, median change in eGFR was 0.0 mL/min/1.73m² in both groups (p=0.71).
In obese hypertensive patients, first-line treatment with eplerenone was not associated with excess renal function decline or clinically significant hyperkalemia compared with irbesartan. These findings support the renal safety of MRA-based first-line therapy in this population.
The pathophysiology of hypertension in obese patients is complex and multifactorial. Obesity is significantly associated with adverse cardiovascular outcomes. The relationship between obesity and hypertension is well described. However, little is known about the impact of aldosterone blockade using eplerenone in...
P. Iliakis, M. Kouremeti, S. Drogkaris et al.· European Heart Journal· 0 citations
The pathophysiology of hypertension in obese patients is complex and multifactorial. Obesity is significantly associated with adverse cardiovascular outcomes. The relationship between obesity and hypertension is well described. However, little is known about the impact of aldosterone blockade using eplerenone in...
M. Kouremeti, P. Iliakis, S. Drogkaris et al.· European Heart Journal· 0 citations
This predefined subgroup analysis of the ESCORT-HT study evaluated the antihypertensive efficacy, organ-protective effects, and safety profile of esaxerenone compared with an angiotensin II receptor blocker (ARB) in patients aged ≥65 years with hypertension on amlodipine, stratified by the presence or absence of type 2...
M. Ohishi, K. Kario, H. Ohbayashi et al.· Hypertension Research· 0 citations
Despite availability of oral antihypertensive therapies, most patients do not achieve hypertension (HTN) control. Zilebesiran is an investigational RNA interference therapeutic, dosed subcutaneously (SC) every 6 months to lower production of hepatic angiotensinogen (AGT), the most upstream precursor of the renin–...
N. Pagidipati, M. Weber, M. Saxena et al.· European Heart Journal· 1 citation
INTRODUCTION
Dysregulated aldosterone plays an important role in the pathogenesis of hypertension (HTN) and chronic kidney disease (CKD). Lorundrostat, a highly selective aldosterone synthase inhibitor, has demonstrated efficacy and safety for uncontrolled HTN (uHTN) and treatment-resistant HTN in multiple well-control...
M. Weir, S. Bhaduri, Keung Lee et al.· Kidney International· 1 citation
The ESCORT-HT study recently demonstrated non-inferiority of esaxerenone to angiotensin II receptor blockers (ARBs) in lowering morning home systolic blood pressure (SBP) in Japanese patients aged ≥65 years with inadequately controlled hypertension on amlodipine. This predefined subgroup analysis of the ESCORT-HT study...
K. Kario, H. Ohbayashi, H. Ishii et al.· Hypertension Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.